ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1158

Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI)

Sofia Torreggiani1, Sara Alehashemi2, Jacob Mitchell1, Gema Souto Adeva1, Bin Lin1, Jenna Wade1, Gina Montealegre Sanchez3, Abdulrahman Alrasheed4, Sibel Balci5, Roberta Berard6, Borzutzky Arturo7, Jürgen Brunner8, Bjoern Buehring9, Al Adba Buthaina10, Caterina Cancrini11, John Carter12, Mireia Corbeto Lopez13, Fabrizio De Benedetti14, Huy Do15, Gregor Dueckers16, Les Folio15, Antonella Insalaco17, Rabia Miray Kisla Ekinci5, Michael Miller18, Marco Montes Cano19, Marie-Paule Morin20, Seza Ozen21, Lucia Pacillo11, Suzanne Ramsey22, Adam Reinhardt23, Dax Rumsey24, Laisa Santiago25, Grant Schulert26, Benjamin Wright27, Adriana de Jesus28 and Raphaela Goldbach-Mansky29, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 3NIAID/NIH, Rockville, MD, 4King Abdullah Specialized Children Hospital, Riyadh, Riyadh, Saudi Arabia, 5Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, 6London Health Sciences Centre, London, ON, Canada, 7Pontificia Universidad Católica de Chile, Santiago, Chile, 8Tirol Kliniken, Innsbruck, Innsbruck, Austria, 9Rheumazentrum Ruhrgebiet, Ruhr-University-Bochum, Herne, Germany, 10Sidra Medicine, Doha, Doha, Qatar, 11Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens’ Hospital Bambino Gesù, University Department of Pediatrics (DPUO); Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy, 12University of South Florida, Tampa, FL, 13Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 14Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 15Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, 16Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Germany, Krefeld, Germany, 17Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 18Feinberg School of Medicine, Northwestern University Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 19Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain, 20Université de Montréal, CHU Sainte-Justine, Montréal, Canada, 21Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 22IWK Health Centre, Dalhousie University, Halifax, NS, Canada, 23Boys Town National Research Hospital, Omaha, Omaha, NE, 24Alberta Health Services – Edmonton Zone (Stollery Children’s Hospital), University of Alberta, Edmonton, AB, Canada, 25Johns Hopkins All Children's Hospital, St. Petersburg, FL, 26PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 27Mayo Clinic, Phoenix, AZ, 28Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, 29Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD

Meeting: ACR Convergence 2020

Keywords: Autoinflammatory diseases, genetics, interferon, interstitial lung disease, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is an autoinflammatory interferonopathy caused by gain-of-function mutations in STING1, characterized by peripheral vasculopathy and interstitial lung disease. Our aim is to describe the clinical and immunological manifestations of SAVI.

Methods: Clinical information on 33 patients with SAVI, based on NIH evaluation (n=15) or on records and samples provided by collaborators (n=18), were retrospectively reviewed. Patients were enrolled in an IRB-approved natural history protocol. The IFN score was calculated as previously described [1]. Features of lung inflammation and damage on Computed Tomography (CT) were scored by a single radiologist (LF). Severe lung disease was defined as presence of at least one characteristic: lung fibrosis, respiratory insufficiency, pulmonary hypertension, or digital clubbing associated with interstitial lung disease on chest CT.

Results: 13/33 (39.4%) patients were female. SAVI was sporadic in 73% and familial in 27%. Heterozygous mutations were disease-causing in 81.8%, however, a p.R281W mutation, present in 6 patients from 4 families, required homozygosity (additive gain-of-function). The p.N154S and p.V155M mutations were most common (27.3% and 24.2% respectively, see Table 1). Disease symptoms presented in the first year of life (75%), with rash (18/31), respiratory symptoms (13/31) and fever (11/31). Table 2 lists clinical and laboratory features in SAVI. The p.N154S mutation is associated with vasculopathy (p=0.03); patients with the p.V155M mutation tend to have more severe lung disease (p=0.2). Median age at last evaluation was 12 years (range 0.4-54.1). 7 patients died at a mean age of 7 years (range 0.4-15); due to respiratory failure n=4, multiorgan failure n=1, sepsis n=1, unknown n=1. In 4/17 the IFN score was negative in whole blood, but positive in PBMCs. Patients failed a mean of 2.1 DMARDs or biologics, 76.6% received steroids. 25 patients were treated with a JAK-inhibitor (baricitinib n=14, tofacitinib n=7, ruxolitinib n=7), for an average of 2.1 years (range 0-5.7). Skin ulcers improved in 10/10, but recurred. Over an average of 2.6 years (range 1.1-3.9), on chest CT, features of inflammation improved in 6/7, with stable/improved damage in 6/7.

Conclusion: SAVI is a severe early-onset interferonopathy, that can lead to amputations, respiratory insufficiency and premature death. SAVI is sporadic in 73%. Most pathogenic STING1 mutations are heterozygous, except for p.R281W, which is disease-causing in homozygosity. With the absence of peripheral disease in 9.4%, SAVI should be suspected in any patient with interstitial lung disease even in the absence of vasculopathy. The p.N154S mutation is associated with vasculopathy, and the p.V155M with more severe lung disease. Rarely, the IFN score can be negative in whole blood and positive in PBMCs. Treatment with JAK inhibitors halted progression of lung damage over an average of 2.3 years, but only partially controlled peripheral vasculopathy and did not normalize the IFN score.

Funding for this study was provided by the Division of Intramural Research, NIAID, NIH

  1. Kim et al. J Interferon Cytokine Res 2018;38:171–85


Disclosure: S. Torreggiani, None; S. Alehashemi, None; J. Mitchell, None; G. Souto Adeva, None; B. Lin, None; J. Wade, None; G. Montealegre Sanchez, None; A. Alrasheed, None; S. Balci, None; R. Berard, None; B. Arturo, None; J. Brunner, None; B. Buehring, None; A. Buthaina, None; C. Cancrini, None; J. Carter, None; M. Corbeto Lopez, None; F. De Benedetti, Novartis, 2, 8, Novimmune, 2, 9, Sobi, 2, 8, 9, Roche, 2, 8, Pfizer, 2, Sanofi, 2, AbbVie, 8; H. Do, None; G. Dueckers, None; L. Folio, None; A. Insalaco, None; R. Kisla Ekinci, None; M. Miller, None; M. Montes Cano, None; M. Morin, None; S. Ozen, SOBI, 1, Novartis, 1; L. Pacillo, None; S. Ramsey, None; A. Reinhardt, None; D. Rumsey, None; L. Santiago, None; G. Schulert, Novartis, 5, Sobi, 5; B. Wright, None; A. de Jesus, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Torreggiani S, Alehashemi S, Mitchell J, Souto Adeva G, Lin B, Wade J, Montealegre Sanchez G, Alrasheed A, Balci S, Berard R, Arturo B, Brunner J, Buehring B, Buthaina A, Cancrini C, Carter J, Corbeto Lopez M, De Benedetti F, Do H, Dueckers G, Folio L, Insalaco A, Kisla Ekinci R, Miller M, Montes Cano M, Morin M, Ozen S, Pacillo L, Ramsey S, Reinhardt A, Rumsey D, Santiago L, Schulert G, Wright B, de Jesus A, Goldbach-Mansky R. Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-features-and-outcomes-in-sting-associated-vasculopathy-with-onset-in-infancy-savi/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-and-outcomes-in-sting-associated-vasculopathy-with-onset-in-infancy-savi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology